Health ❯ Healthcare ❯ Clinical Trials ❯ Phase III Trials

Patient Outcomes

FDA Approves One-Time Intrathecal Gene Therapy Itvisma for Older SMA Patients

The decision follows phase 3 data showing statistically meaningful one-year motor improvement in children and teenagers.

Shorter, Chemo-Free Strategies Match or Beat Standard Care in Adult Leukemias at ASH